Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 0.83% 121.80 121.60 122.00 122.60 119.80 122.40 1,331,766 15:15:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 186.1 17.5 7.0 1,294

Ip Share Discussion Threads

Showing 2276 to 2299 of 2425 messages
Chat Pages: 97  96  95  94  93  92  91  90  89  88  87  86  Older
DateSubjectAuthorDiscuss
31/3/2021
22:56
"The float will also mean a likely big payday for FTSE250-listed intellectual property rights investor IP Group, which holds a 15% stake in Nanopore valued at £340million. Russ Mould, investment director at AJ Bell, said: “A successful float by Oxford Nanopore – the third unicorn with a $1-billion-plus valuation to emerge from IP Group’s investments, after Ceres Power and Hinge Health – would be a huge affirmation of the company’s business model.” https://www.standard.co.uk/business/pharmaceuticals/oxford-nanopore-gene-sequenced-covid19-2-3-billion-float-b927022.html
eeza
31/3/2021
20:15
https://www.telegraph.co.uk/technology/2021/03/31/forget-deliveroo-ex-woodford-pick-real-gem/
eeza
31/3/2021
09:08
Only 15%.Yes, we all know. But only 15% is at least half the mkt cap of IPO, and could be 80%.And there are 3 or 400 other investments too iirc.While nano is the star, there are others recently matured (and sold cheaply) and others maturing. IPO are full of cash from Ceres.
pierre oreilly
31/3/2021
09:06
edward, ONT at £2.2bn currently = 32p of IPGroup shareprice, as at 31/12/2020 If it doubles to £4.4bn adds another 32p £7bn adds over 60p Current NAV at end of 2020 is 125p
bamboo2
31/3/2021
09:06
I'm guessing ONT will float at closer to 20Bn than the 4Bn often quoted. They are keeping very quiet about their 2020 sales growth, I think it will blow away expectations. Pacbio and Illumina had flat or lower sales in 2020 despite massive demand for sequencing, guess who's taking their market share? Also ONT make the consumables so it's also a bit like ThermoFisher
wetpantz
31/3/2021
09:02
even with my basic maths 15% of £4bn is £600m not £340mn in the books.
edwardt
31/3/2021
09:01
DNL for eg
babbler
31/3/2021
09:00
Looks like the market has finally woken up to the Nanapore news - shareprice up by 4% in the first hour of trading ! 😊
masurenguy
31/3/2021
08:59
I'd go for an in specie Divi of nano shares given the chance. Not sure why they're floating only in London - I'd hold and await the inevitable us dual listing.Strange someone thinks nano MAY be a bill company, I'd say it'll be close to 8 bill than 1. Another 15p min to go on IPO as the float gets nearer. Plus there's lots more going on at IPO. Well ndervalued due to Invesco/Woodford, another 30p as that situation corrects.
pierre oreilly
31/3/2021
08:53
Be careful with the maths as IPO only own 15%
red army
31/3/2021
08:51
wakey wakey indeed.
edwardt
31/3/2021
08:36
Penny dropping. Resistance 124 could go today. Next line up is 134.
bamboo2
31/3/2021
08:25
nearest comparator stock i can find to ont is pacific bio. similar revenue. for the lazy who don't want to think about margins and forward guidance and remove the uk £100m+ contract for ont - you get the idea why the range is 4-7bn not the 2.2bn on the books at ip. what am i missing please?
edwardt
31/3/2021
07:23
Poor Woodford holders - their stake sold at less than 10th of float price
edwardt
31/3/2021
00:19
Top biotech’s £2bn float boosts City Oxford Nanopore chooses London over New York One of Britain’s most promising biotech companies is planning to float on the London Stock Exchange with a potential valuation of more than £2bn, in a boost for the UK’s life sciences sector and the City. The IPO will deliver a windfall to existing investors, although it is another blow for investors in Neil Woodford’s failed income fund. His firm had a stake of about 12% before its implosion. Large investors also include IP Group, the FTSE 250 intellectual property commercialisation company, which provided seed funding. IP Group confirmed that it holds a 15% in Oxford Nanopore, valued at £340.3m. Shares in IP Group closed up 1¼p at 121¼p, and have risen by more than a fifth this year. A successful float of Oxford Nanopore would make it the third unicorn with a $1bn-plus valuation to emerge from IP Group’s investments. Complete article: https://www.thetimes.co.uk/article/top-biotech-s-2bn-float-boosts-city-zkdc58jf2
masurenguy
30/3/2021
23:14
In specie distribution of ONT stock would be a winner, a large proportion of investors hold IP Group primarily for ONT exposure. IPO should announce this ahead of the float.
wetpantz
30/3/2021
22:38
The Investors Chronicle trick works for the FT as well
scubadiverr
30/3/2021
22:13
Timing matters. No way to know if the optimum window will have closed by H2.
p1nkfish
30/3/2021
21:41
edwardt, thanks, I couldn't access the FT article. This will be the first IPGroup float for a long long time without Woodford involvement. Arguably, many of the prior listings involved companies that were obviously not ready to stand on their own two feet. I would include CWR in that category. Hopefully, ONT will display enough maturity to thrive on the market. It helps to have friends in high places!
bamboo2
30/3/2021
21:31
Happy it is at least listing on lSE. I am serious up group should pass us the shares in specie net of their fees..
edwardt
30/3/2021
21:29
Ft are going with a float value of between 4 to 7 bn.
edwardt
30/3/2021
20:32
Just found this from Bloomberg Https://www.bloomberg.com/news/articles/2021-03-30/oxford-nanopore-plans-listing-in-big-boost-to-u-k-ipo-market DNA sequencing firm Oxford Nanopore Technologies Ltd. plans to list on the London Stock Exchange in the second half of the year, delivering a major win for the City in its effort to position itself as an attractive venue for initial public offerings in a post-Brexit world. A listing will give the company access to “deeper, international pools of capital” for its growth plans, Oxford Nanopore said in a statement on its website on Tuesday. The timing of the IPO is dependent on market conditions, it said. IP Group Plc, which owns 15% of Oxford Nanopore, rose 1.5% to 121.80 pence at 12:48 p.m. in London. Oxford Nanopore is worth 2.3 billion pounds based on the valuation that IP Group assigns to its stake. Analysts at Berenberg wrote in a report this month that the Oxford Nanopore “could comfortably” reach a valuation of more than 4 billion pounds in its next fundraising. Oxford Nanopore’s IPO plan comes a day before food-delivery startup Deliveroo Holdings Plc is set to start trading on the LSE. The U.K. is keen to keep its homegrown unicorns from fleeing to the U.S. in search of investors, and is examining an array of new rules including giving founders greater control over their companies even going public, like allowing dual-class share structures on the premium segment of the listing venue. Like other companies tapping the IPO market, Oxford Nanopore, a spinout from the University of Oxford, is listing on the back of a pandemic boost. The company supplies the U.K. with LamPORE tests, which use DNA and RNA sequencing to detect the SARS-CoV-2 virus that causes Covid-19.
bamboo2
30/3/2021
20:27
edwardt, do you have a link that refers to a current valuation of £2.2bn, or is it based on something else? I think we have to wait until the end of 2021 to see that kind of valuation.
bamboo2
30/3/2021
20:24
This is the text from the ONT website Oxford Nanopore Technologies Limited (“the Company”) has today informed its shareholders that it has started the process of preparing for a potential initial public offering (the “IPO”). While the timing of a potential IPO is dependent on market conditions and other matters not fully within the Company’s control, at this stage the Company expects that the IPO would occur in the second half of 2021 on the London Stock Exchange. Oxford Nanopore is driven by a clear ambition: to be a global company that enables the analysis of anything by anyone, anywhere. Our disruptive approach is designed to make biological analysis better, faster, and more accessible & affordable, broadening its potential applications and amplifying its positive impact on society. Today we serve thousands of customers, across a wide range of scientific communities, in more than 100 countries around the world. Scientists are using our DNA/RNA sequencing technology to answer some of society’s most urgent and important questions, including those concerned with biomedical, pathogen, plant and animal scientific research, infectious disease, critical viral surveillance, optimising crop efficiency, ensuring food security and understanding how our environment is changing. Innovation is at our heart. We have built an in-house and licensed portfolio of more than 1,350 patents and applications, and we constantly drive improvements in our technology platform to further enhance our products and their capabilities. Innovation is also central to our manufacturing and in 2019 we opened a high-tech manufacturing facility designed to scale up high quality production capacity for the coming years. We believe that an IPO is the start of the next phase of our journey. Gaining access to deeper, international pools of capital would support our ambitious growth plans, enhancing our ability to innovate and scale our manufacturing and commercial functions. It would, we believe, provide us with the resources and flexibility to fulfil our long-term potential. Why now? In 2015, Oxford Nanopore started to sell its first commercial device, the MinION portable DNA/RNA sequencer. Since then, we have expanded our product range to include both even smaller formats and larger high throughput sequencing devices suitable for population-scale human genomics. The use of nanopore sequencing has expanded in a broad scientific community. More than 1,500 scientific publications now illustrate the use of our technology. We have worked continuously to evolve the technology and build the business since then, however, the last year has been transformative for Oxford Nanopore Technologies. Highlights include: Innovations that enhanced our existing technology platform, which can characterise a broader picture of genetic diversity, at scale, than traditional sequencing technologies. We have released new analysis algorithms, chemistries, and platform improvements that drive even higher performance in both data yields and accuracy. Our technology already provides a unique combination of features in the market: the ability to sequence both short or ultra-long fragments of DNA, the ability to stream sequence data in real time, the ability to sequence the native DNA or RNA molecule and the ability to deploy sequencing in a range of formats from portable pocket-sized devices to ultra-high throughput benchtop machines. In combination with the recently increased performance, we believe that we are at the right point in our journey to scale up our provision of nanopore sequencing to the market. Read more Supporting users around the world to sequence the virus that causes COVID-19, facilitating continual surveillance of the virus. Around a fifth (~170,000) of the SARS-CoV-2 virus genomes in the global database GISAID were generated on one of our devices, with nanopore data uploaded by scientists from more than 85 countries. The role of genomics in infectious disease is now better understood. Maturing our infrastructure around regulated products. Our development of a high-performance diagnostic test for the detection of SARS-CoV-2 drove an acceleration in the development of our infrastructure, processes and talent required to explore opportunities in diagnostic markets beyond COVID-19. This rapid maturation of this part of our business also helps us to prepare for future ‘applied markets’. Manufacturing scale-up. Expansion of our new MinION Building high-tech manufacturing facility in Oxford has prepared us for the next scale of operational growth. These advances made 2020 a pivotal year for us. However, it is clear to us that we are still only in the foothills of what is possible. The challenging events of 2020 demonstrated the importance of life sciences in understanding and improving the world around us. Our DNA and RNA sequencing technology is well-positioned for accelerated use across multiple applications; we believe that there is huge potential for near-sample, rapid, low cost, sequencing-based analyses across scientific research, healthcare and industrial settings. These include the long-term potential to provide rapid biological insights in infectious disease, immune profiling and cancer, as well as in food safety, agriculture or other industrial environments. Most importantly, we sincerely thank our global community of collaborative and innovative customers, our international shareholders and all our colleagues inside the company and in our supply and innovation network for the support in reaching this point. We are looking forward to continuing the journey with you, and getting closer to enabling an Internet of Living Things that has a profoundly positive impact on communities. In the meantime, we remain as focused as ever on continuing to support our customers, innovate and position the company for long-term growth. Dr Gordon Sanghera, CEO
bamboo2
Chat Pages: 97  96  95  94  93  92  91  90  89  88  87  86  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 14:38:57